Aviptadil Placebo

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Covid19

Phase 3

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

CompletedNCT04843761

National Institute of Allergy and Infectious Diseases (NIAID)Covid19

Start: 2021-04-20End: 2022-11-20Updated: 2025-10-24

Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

CompletedNCT06729606

National Institute of Allergy and Infectious Diseases (NIAID)Covid19

Start: 2021-04-20End: 2022-11-20Updated: 2025-10-09

Related Papers

Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.

2023-06-1913 citations